Business, energy, technology, markets and global industry news from Business News Today

American Urological Association

PharmaDeviceNews American Urological Association
Representative image of a urologist discussing overactive bladder and benign prostatic hyperplasia treatment data with an older male patient, reflecting Sumitomo Pharma America’s AUA 2026 vibegron findings in men aged 75 and older.
Pharma & Biotech

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Read More
Representative image: A clinician reviews bladder imaging during a urology consultation, reflecting Ferring Pharmaceuticals’ ADSTILADRIN re-induction data and the growing focus on bladder-sparing treatment strategies for BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?

Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.

Read More